
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 09:45:48 CEST | Grünenthal Group | Pressemeddelelse
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.


















